INK128,
MLN0128,
TAK-228,
1224844-38-5,
Sapanisertib,
INK-128,
MLN0128,
INK 128,
INK128,
INK 128 (MLN0128),
TAK-228,
UNII-JGH0DF1U03,
MLN-0128,
5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine,
JGH0DF1U03,
3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine,
5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine,
C15H15N7O,
5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine,
Sapanisertib; INK128,
Sapanisertib (USAN/INN),
Sapanisertib [USAN:INN],
MLS006011012,
GTPL7933,
SCHEMBL7902875,
CHEMBL3545097,
CHEBI:91450,
EX-A951,
INK-128/INK128,
SYN1157,
BDBM315477,
HMS3656H12,
INK-128;Sapanisertib;MLN0128,
AOB87177,
INK-0128,
2477AH,
MFCD22124893,
s2811,
ZINC73069271,
AKOS025149512,
US10172858, Table 1.1,
BCP9000789,
CS-0557,
DB11836,
SB16566,
US10172858, Table 1.22,
NCGC00346654-01,
NCGC00346654-10,
AC-26848,
AK175515,
AS-16294,
HY-13328,
SMR004702810,
BCP0726000086,
A8551,
FT-0700125,
SW220210-1,
KS-00000633,
A11461,
D11183,
W-5898,
Sapanisertib (INK 128, MLN0128,TAK-228),
INK-128,CAS:1224844-38-5,
J-004811,
1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-(2-amino-5-benzoxazolyl)-1-(1-methylethyl)-,
5-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine,
INK-128|||MLN-0128|||5-(4-Amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine,
Sapanisertib [INN],
D03DPZ,
C572449,
Sapanisertib, 98%, a potent and selective mTOR inhibitor - 10MG 10mg,